🌍·11h agodiscovery
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.
Publisher
B
Bitget
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Bitget
- Region
- Global
- Scope
- discovery
- Published
- July 9, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Bitget
Scope: discovery
Related coverage
More related coverage
Health Canada Recalls and Safety Alerts/1h ago
Astral 150™
An internal electrical component (supercapacitor) may leak electrolyte over time. In rare cases, thi...
UK Health Security Agency/2h ago
Environmental monitoring following the Grenfell Tower fire
Air quality reports for the survivors and residents of the area surrounding Grenfell Tower.
Microbioz India/2h ago
Science in Motion: The Technologies Shaping Tomorrow's Pharmaceutical Industry
simplywall.st/2h ago